DS
MCRB icon

David Shaw’s Seres Therapeutics MCRB Stock Holding History

David Shaw’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-24,318
Closed -$376K – 4689
2024
Q1 		$376K Buy
24,318
+15,892
+189% +$343K ﹤0.01% 3621
2023
Q4 		$236K Buy
+8,426
New +$221K ﹤0.01% 3827
2022
Q3 		– Sell
-2,157
Closed -$148K – 5380
2022
Q2 		$148K Sell
2,157
-2,625
-55% -$226K ﹤0.01% 4646
2022
Q1 		$681K Buy
4,782
+3,325
+228% +$511K ﹤0.01% 4179
2021
Q4 		$243K Buy
1,457
+648
+80% +$103K ﹤0.01% 4783
2021
Q3 		$113K Sell
809
-1,815
-69% -$355K ﹤0.01% 4701
2021
Q2 		$1.25M Buy
2,624
+18
+0.7% +$7.59K ﹤0.01% 3357
2021
Q1 		$1.07M Sell
2,606
-17,144
-87% -$7.89M ﹤0.01% 3057
2020
Q4 		$9.68M Sell
19,750
-5,147
-21% -$3.01M 0.01% 1398
2020
Q3 		$14.1M Sell
24,897
-15,861
-39% -$5.27M 0.01% 1018
2020
Q2 		$3.88M Buy
40,758
+16,299
+67% +$1.43M ﹤0.01% 1855
2020
Q1 		$1.75M Buy
24,459
+6,388
+35% +$428K ﹤0.01% 2275
2019
Q4 		$1.25M Buy
18,071
+5,172
+40% +$384K ﹤0.01% 2827
2019
Q3 		$1.03M Sell
12,899
-2,892
-18% -$191K ﹤0.01% 2806
2019
Q2 		$1.02M Buy
15,791
+1,526
+11% +$145K ﹤0.01% 2668
2019
Q1 		$1.96M Sell
14,265
-1,132
-7% -$138K ﹤0.01% 2172
2018
Q4 		$1.39M Buy
15,397
+860
+6% +$120K ﹤0.01% 2430
2018
Q3 		$2.21M Buy
14,537
+89
+0.6% +$14.4K ﹤0.01% 2132
2018
Q2 		$2.48M Sell
14,448
-567
-4% -$92.6K ﹤0.01% 2059
2018
Q1 		$2.2M Sell
15,015
-4,007
-21% -$768K ﹤0.01% 1983
2017
Q4 		$3.86M Sell
19,022
-8,415
-31% -$1.73M 0.01% 1670
2017
Q3 		$8.8M Buy
27,437
+1,074
+4% +$294K 0.01% 1022
2017
Q2 		$5.96M Sell
26,363
-2,552
-9% -$524K 0.01% 1218
2017
Q1 		$6.52M Buy
28,915
+1,996
+7% +$405K 0.01% 1117
2016
Q4 		$5.33M Buy
26,919
+654
+2% +$143K 0.01% 1319
2016
Q3 		$6.46M Buy
26,265
+25,790
+5,429% +$9.05M 0.01% 1135
2016
Q2 		$276K Buy
+475
New +$279K ﹤0.01% 3065

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

David Shaw's MCRB Position: Q2 2024 in Review

David Shaw sold out of Seres Therapeutics (MCRB) in Q2 2024, closing a stake of 24,318 shares — an estimated $376K sold.

David Shaw first reported a position in MCRB in Q2 2016 and held it in 27 quarters. The position peaked at $14.1M in Q3 2020. 93 funds tracked by Wall St. Rank hold MCRB as of Q2 2024.

  • David Shaw reported no remaining Seres Therapeutics position as of Q2 2024 after selling out during the quarter.
  • David Shaw sold 24,318 Seres Therapeutics shares in Q2 2024, an estimated $376K.
  • David Shaw first reported a position in Seres Therapeutics in Q2 2016 and held it in 27 quarters.
  • David Shaw's Seres Therapeutics position peaked at $14.1M in Q3 2020.
  • 93 funds tracked by Wall St. Rank held Seres Therapeutics as of Q2 2024.

Based on D.E. Shaw & Co's 13F filing for Q2 2024, filed 14 Aug 2024.